Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bisnorcymserine - Annovis Bio

Drug Profile

Bisnorcymserine - Annovis Bio

Alternative Names: ANVS-301; Bisnorcymcerine; BNC

Latest Information Update: 04 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA)
  • Developer Annovis Bio; Cenomed BioSciences; National Institute on Aging; National Institutes of Health (USA)
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease
  • Discontinued Poisoning

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 08 Jan 2019 Bisnorcymserine is still in phase I trials for Alzheimer's disease (In volunteers, In the elderly) in the US (NCT01747213)
  • 08 Jan 2019 National Institute on Aging completes a phase-I clinical trial in Alzheimer's disease (In volunteers, In the elderly) in USA (PO) (NCT01747213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top